PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35445730-0	2022	EGFR inhibition reverses epithelial-mesenchymal transition, and decreases tamoxifen resistance via Snail and Twist downregulation in breast cancer cells.	Tamoxifen	74-83	epidermal growth factor receptor	Homo sapiens	0-4	
35445730-6	2022	In addition, it was observed that the inhibition of epidermal growth factor receptor (EGFR) reversed the EMT phenotype in tamoxifen-resistant MCF7 (MCF-7/TR) cells via the downregulation of Snail and Twist.	Tamoxifen	122-131	epidermal growth factor receptor	Homo sapiens	52-84	
35445730-6	2022	In addition, it was observed that the inhibition of epidermal growth factor receptor (EGFR) reversed the EMT phenotype in tamoxifen-resistant MCF7 (MCF-7/TR) cells via the downregulation of Snail and Twist.	Tamoxifen	122-131	epidermal growth factor receptor	Homo sapiens	86-90	
35445730-7	2022	Notably, the EGFR inhibitor, gefitinib, decreased tamoxifen resistance, migration and invasion through the inhibition of Snail and Twist.	Tamoxifen	50-59	epidermal growth factor receptor	Homo sapiens	13-17	
35445730-8	2022	On the whole, the results of the present study suggest that EGFR may be a promising therapeutic target for tamoxifen-resistant breast cancer.	Tamoxifen	107-116	epidermal growth factor receptor	Homo sapiens	60-64